Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-2 empagliflozin adjunct to insulin in adults with type 1 diabetes
NL-OMON44884Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in diabetes mellitus type 1 (T1D), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Jul 2015; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON44884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44884.